10.22376/ijpbs.2019.10.1.p1-12 Volume 12 Issue 3 2021 (July-September) The incidence of infections caused by the multidrug-resistant (MDR) Gram-positive bacteria is increasing despite the advances in antibacterial therapy over the last few years. The most problematic pathogens include Methicillin-resistant staphylococcus aureus (MRSA). Methicillin resistance in Staph.aureus is associated with resistance to several commonly used antimicrobial agents such as Amoxicillin-Clavulanic Acid, Ceftizoxime, Ofloxacin, Amikacin, Azithromycin and Clindamycin. Glycopeptides such as Vancomycin have traditionally been considered as the drug of choice in the treatment of infection caused by these organisms. But Strains of MRSA with reduced susceptibility to glycopeptides have been reported from several parts of the world including India. Other than this linezolid a novel Oxazolidinone has potent activity against a variety of Gram-positive bacteria including MRSA and are used to treat more severe infections that do not respond to glycopeptides such as Vancomycin. But Linezolid resistant Staph.aureus (LRSA) first isolated in 2001, since then many other cases of Linezolid resistant MRSA have been reported in various parts of the world. The aim of this study was to compare and analyse the Resistance of vancomycin and linezolid Against MRSA in a Tertiary Care Centre at Southern Rajasthan. Modified Kirby Baurer disc diffusion method was used for antimicrobial sensitivity testing of all samples. Vancomycin and Linezolid which were having 100% sensitivity to MRSA earlier even found resistance in some isolates of MRSA in the present study. The prevalence rate of vancomycin resistance (VRSA)-13% and Linezolid resistance (LRSA)–12% was found in clinical isolates of Staph. Aureus samples. This has resulted in a situation in which very few options are available for treating infections caused by MRSA. So urgent measures are required to prevent the development of resistance among them and the same time there is simultaneous need for development of newer agents active against VRSA and LRSA. Dr. Harcharan Singh, Dr. Vinod Kumar Chhipa, Dr. Vimlesh Kumar Meena and Dr. Monika Gaur Staphylococcus aureus, Methicillin, Resistant, Vancomycin, Linezolid. 28-32